Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective

Cancer Treatment Reviews

Volumn 40, Issue 9, 2014, Pages 1065-1072

  Clarke, J M ^a   Hurwitz, H I ^a   Rangwala, F ^a,b  

^a DUKE CANCER INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Angiogenesis; Antiangiogenic; Bevacizumab; Metastatic colorectal cancer; Ramucirumab; Regorafenib; Ziv aflibercept

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; REGORAFENIB; CARBANILAMIDE DERIVATIVE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BINDING AFFINITY; BINDING SITE; BLEEDING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IC50; INFECTION; METASTATIC COLORECTAL CANCER; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; ULCER; VENOUS THROMBOEMBOLISM; ANIMAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PHENYLUREA COMPOUNDS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR MICROENVIRONMENT;

EID: 84923279264     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.07.001     Document Type: Review

References (62)

1. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl. 1):2-10.
2. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
3. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
4. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
5. Dikov M.M., Ohm J.E., Ray N., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005, 174:215-222.
6. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012.
7. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
8. Wilhelm S.M., Dumas J., Adnane L., et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011, 129:245-255.
9. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). ASCO Meeting Abstracts 32:LBA7, 2014.
10. Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39.
11. Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011, 13:97-102.
12. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
13. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
14. Fischer C., Mazzone M., Jonckx B., et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008, 8:942-956.
15. Wei S.C., Tsao P.N., Yu S.C., et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005, 54:666-672.
16. Kopetz S., Hoff P.M., Morris J.S., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010, 28:453-459.
17. Loupakis F., Cremolini C., Fioravanti A., et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011, 104:1262-1269.
18. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583.
19. Hedlund E.M., Yang X., Zhang Y., et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 2013, 110:654-659.
20. Albrecht I., Kopfstein L., Strittmatter K., et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 2010, 5:e14109.
21. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
22. Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012, 15:171-185.
23. Chiron M., Bagley R.G., Pollard J., et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther 2014.
24. Lu D., Shen J., Vil M.D., et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003, 278:43496-43507.
25. Miao H.Q., Hu K., Jimenez X., et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006, 345:438-445.
26. Schmieder R EP, Scholz A, Bhargava A, Wilhelm SM, Zopf D. Regorafenib (BAY 73-4506): anti-metastatic activity in a mouse model of colorectal cancer. In: Presented at the AACR Annual Meeting, Chicago, IL, March 31-April 4, 2012, 2012.
27. Strickler J.H., Hurwitz H.I. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 2012, 17:513-524.
28. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
29. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
30. Fuchs C.S., Marshall J., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-690.
31. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
32. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008, 26:3523-3529.
33. Reinacher-Schick AC, Kubicka S, Freier W, et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). ASCO Meeting Abstracts 26:4030, 2008 .
34. Schmiegel WH, Reinacher-Schick A, Freier W, et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): a randomized phase II study of the AIO GI tumor study group. ASCO Meeting Abstracts 25:4034, 2007.
35. Bendell J.C., Bekaii-Saab T.S., Cohn A.L., et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012, 17:1486-1495.
36. Thomas SP, Badarinath S, Greenberg RH, et al. MAVERICC: a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 30:TPS3635, 2012.
37. Pericay C.F.G., Saunders M., Thomas A., Roh J.K., Lopez R., et al. Phase 2 randomized, noncomparative, open-label, study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012, 24:16.
38. Garcia-Carbonero R, Rivera F, Maurel J, et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. ASCO Meeting Abstracts 30:533, 2012.
39. Garcia-Carbonero R., Rivera F., Maurel J., et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014, 19:350-351.
40. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
41. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
42. Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
43. Morlock R, Yu E, Ray J. A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV. ASCO Meeting Abstracts 31:417, 2013.
44. Grothey A, Tabernero J, Rougier P, et al. A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). ASCO Meeting Abstracts 30:TPS3634, 2012.
45. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
46. Bottsford-Miller J.N., Coleman R.L., Sood A.K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012, 30:4026-4034.
47. Clarke J.M., Hurwitz H.I. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol 2013, 4:253-263.
48. Lieu CH, Tran HT, Jiang Z, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. ASCO Meeting Abstracts 29:3533, 2011.
49. Lieu C.H., Tran H., Jiang Z.Q., et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 2013, 8:e77117.
50. Li J.L., Sainson R.C., Oon C.E., et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011, 71:6073-6083.
51. Jenkins D.W., Ross S., Veldman-Jones M., et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther 2012, 11:1650-1660.
52. Daly C., Eichten A., Castanaro C., et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013, 73:108-118.
53. Eatock M.M., Tebbutt N.C., Bampton C.L., et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2013, 24:710-718.
54. Cunha S.I., Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011, 117:6999-7006.
55. Goff LW, Cohen RB, Berlin J, et al.: Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF{beta} receptor involved in tumor angiogenesis. ASCO Meeting Abstracts 29:3009, 2011.
56. Moreno Garcia V., Basu B., Molife L.R., et al. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012, 18:3750-3761.
57. Lambrechts D., Lenz H.J., de Haas S., et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013.
58. Hurwitz H.I., Douglas P.S., Middleton J.P., et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013, 18:273-280.
59. Hegde P.S., Jubb A.M., Chen D., et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 2013, 19:929-937.
60. Jayson GC dHS, Delmar P, Miles DW, Shah MA, Van Cutsem E, Carmeliet P HP, Wild N, Scherer SJ: Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. 2011 European Multidisciplinary Cancer Congress., 2011.
61. Weickhardt AJ, Williams D, Lee C, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study. ASCO Meeting Abstracts 29:3531, 2011.
62. Diaz L.A., Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.